Although GSI nirogacestat was approved by FDA for desmoid tumors and could be used off-label in other cancer types including the breast, GSI activity against NOTCH rearrangement and mutations could display significant differences by rearrangement product and location of the mutation, limiting their use as a general strategy for all NOTCH2 alterations. The gene discussed is NOTCH2; the disease is cancer.